Amphastar Pharmaceuticals (AMPH) EBITDA (2013 - 2026)
Amphastar Pharmaceuticals (AMPH) EBITDA from Jun 30, 2013 to Mar 31, 2026. The TTM Amphastar Pharmaceuticals (AMPH) EBITDA is $149M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Amphastar Pharmaceuticals (AMPH) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -32.43% |
| 3 Years TTM | +3.99% |
| 5 Years TTM | +45.01% |
| 10 Years TTM | +25.06% |
| All Time TTM | +86.24% |
Annual EBITDA change of Amphastar Pharmaceuticals (AMPH)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | $22M | -87.38% |
| 2025 | $172M | -26.37% |
| 2024 | $234M | +4.92% |
| 2023 | $223M | +85.46% |
| 2022 | $120M | +49.91% |
| 2021 | $80M | +300.95% |
| 2020 | $20M | +184.62% |
| 2019 | $7.02M | -373.15% |
| 2018 | -$2.57M | -149.90% |
| 2017 | $5.15M | -81.30% |
| 2016 | $28M | +523.08% |
| 2015 | $4.42M | -181.10% |
| 2014 | -$5.45M | -119.02% |
| 2013 | $29M | -18.23% |
| 2012 | $35M | N/A |
Comparison Amphastar Pharmaceuticals (AMPH) five years EBITDA CAGR with competitors
Amphastar Pharmaceuticals (AMPH) five years EBITDA CAGR is 45.02%.